Printer Friendly

KODAK'S STERLING WINTHROP LAUNCHES MRI CONTRAST AGENT: UNDERSCORES KODAK'S LEADERSH IN IMAGING, HEALTH

 ROCHESTER, N.Y., Jan. 15 /PRNewswire/ -- Commercial availability of Omniscan (gadodiamide) Injection by Sterling Winthrop Inc.'s Sanofi Winthrop pharmaceuticals unit underscores the company's continued leadership in diagnostic imaging, one of the key components of its strategy for leadership in the pharmaceutical industry says Kay R. Whitmore, Chairman and CEO of Eastman Kodak Company (NYSE: EK).
 "Omniscan is the newest product in a growing family of innovative diagnostic imaging agents," said Wilbur J. Prezzano, president of Kodak's Health Group. "With the addition of Omniscan to Sanofi Winthrop's diagnostic imaging franchise, which includes Omnipaque contrast agent, radiologists have a single source for MRI enhancing agents, as well as contrast agents for X-ray and CT scanning."
 Omniscan is the first of several innovative imaging agents from Sterling Winthrop's pharmaceutical research and development pipeline, which was described by the company at a meeting with the financial community in December 1992. These products, which result from Sterling Winthrop's strong commitment to R&D efforts in contrast media, will continue to assure the company's leadership in this important market.
 Omniscan received approval by the U.S. Food and Drug Administration for marketing in the U.S. It was specifically developed to enhance diagnostic images of the central nervous system obtained through magnetic resonance imaging procedures (MRI).
 Nearly six million MRI procedures were performed in 1991, an almost 300 percent increase from 1987. Approximately one third involved the use of a contrast agent during the procedure.
 Sterling Winthrop is a leader in diagnostic imaging agents with Omnipaque (iohexol) Injection, the leading nonionic contrast agent in the U.S. for X-ray and CT scan imaging.
 "Sterling Winthrop is the cornerstone of Kodak's vision for leadership in health care," Prezzano continued. "Sterling Winthrop's position in pharmaceuticals and consumer health products enhances the Health Group's strong presence in X-ray imaging, clinical diagnostics and household products."
 -0- 1/15/93
 /CONTACT: Paul C. Allen of Eastman Kodak Company, 716-724-5802/
 (EK)


CO: Eastman Kodak Company ST: New York IN: SU:

KK -- CL005 -- 5253 01/15/93 09:45 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 1993
Words:338
Previous Article:WHITMAN CORPORATION ANNOUNCES PUBLIC OFFERING
Next Article:SIGNIFICANT GROWTH PREDICTED IN '93 FOR CONTACT LENS MARKET; NEW PRODUCTS OFFER CONSUMERS MORE CHOICES
Topics:


Related Articles
KODAK CEO SAYS COMPANY IS OPERATING DIFFERENTLY
KODAK REPORTS RECORD SALES, HIGHER EARNINGS FOR 1992 SECOND QUARTER
KODAK & STERLING WINTHROP DESCRIBE SUCCESSES SINCE ACQUISITION
KODAK REPORTS FIRST QUARTER RESULTS;IMPROVED OPERATING PERFORMANCE
KODAK'S CEO UNVEILS NEW CORPORATE STRATEGY
DUFF & PHELPS PLACES EASTMAN KODAK DEBT ON RATING WATCH--UP
KODAK ANNOUNCES NEW CORPORATE STRUCTURE
DUFF & PHELPS NOTES CONTINUED PROGRESS IN DIVESTITURE PROGRAM
KODAK ANNOUNCES TENDER OFFER; DETAILS DEBT REDUCTION PLAN
KODAK COMPLETES STERLING WINTHROP SALE TO SMITHKLINE BEECHAM

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters